OROS methylphenidate HCl

DRUG4 trials

Sponsors

Alza Corporation, DE, USA, Massachusetts General Hospital, Janssen Korea, Ltd., Korea

Conditions

Attention Deficit Disorder With HyperactivityAttention Deficit Hyperactivity DisorderHealthy Volunteers

Phase 3

A Multicenter Study Comparing the Efficacy and Safety of OROS Methylphenidate HCl, Ritalin (Methylphenidate HCl) and Placebo in Children With Attention Deficit Hyperactivity Disorder

CompletedNCT00269802

Alza Corporation, DE, USAAttention Deficit Hyperactivity Disorder

End: 1999-02-28Updated: 2011-06-10

A Comparative Effectiveness Study Evaluating OROS Methylphenidate HCl, Ritalin (Methylphenidate HCl), and Placebo for the Treatment of Attention Deficit Hyperactivity Disorder in Children

CompletedNCT00269789

Alza Corporation, DE, USAAttention Deficit Hyperactivity Disorder

Start: 1998-03-31End: 1998-05-31Updated: 2011-06-10

Phase 4

A Double-blind Randomized, Placebo-controlled, Crossover Study of Single Doses of OROS Methylphenidate Hydrochloride (CONCERTA) and Long-acting Methylphenidate Hydrochloride (RITALIN LA) in Healthy Adults

CompletedNCT00302354

Massachusetts General HospitalHealthy Volunteers

Start: 2004-12-31End: 2005-09-30Target: 50Updated: 2011-07-12

An Efficacy Study of Osmotic Release Oral System (OROS) Methylphenidate in Participants With Attention-Deficit/Hyperactivity Disorder (ADHD)

CompletedNCT01060150

Janssen Korea, Ltd., KoreaAttention Deficit Disorder With Hyperactivity

Start: 2008-07-31End: 2010-04-30Updated: 2013-08-23